1. Home
  2. CCCX vs OLMA Comparison

CCCX vs OLMA Comparison

Compare CCCX & OLMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CCCX
  • OLMA
  • Stock Information
  • Founded
  • CCCX 2024
  • OLMA 2006
  • Country
  • CCCX United States
  • OLMA United States
  • Employees
  • CCCX N/A
  • OLMA N/A
  • Industry
  • CCCX Blank Checks
  • OLMA Biotechnology: Pharmaceutical Preparations
  • Sector
  • CCCX Finance
  • OLMA Health Care
  • Exchange
  • CCCX Nasdaq
  • OLMA Nasdaq
  • Market Cap
  • CCCX 681.3M
  • OLMA 560.7M
  • IPO Year
  • CCCX 2025
  • OLMA 2020
  • Fundamental
  • Price
  • CCCX $14.45
  • OLMA $11.10
  • Analyst Decision
  • CCCX
  • OLMA Strong Buy
  • Analyst Count
  • CCCX 0
  • OLMA 5
  • Target Price
  • CCCX N/A
  • OLMA $24.00
  • AVG Volume (30 Days)
  • CCCX 2.7M
  • OLMA 1.2M
  • Earning Date
  • CCCX 01-01-0001
  • OLMA 11-11-2025
  • Dividend Yield
  • CCCX N/A
  • OLMA N/A
  • EPS Growth
  • CCCX N/A
  • OLMA N/A
  • EPS
  • CCCX 0.14
  • OLMA N/A
  • Revenue
  • CCCX N/A
  • OLMA N/A
  • Revenue This Year
  • CCCX N/A
  • OLMA N/A
  • Revenue Next Year
  • CCCX N/A
  • OLMA N/A
  • P/E Ratio
  • CCCX $106.05
  • OLMA N/A
  • Revenue Growth
  • CCCX N/A
  • OLMA N/A
  • 52 Week Low
  • CCCX $10.03
  • OLMA $2.86
  • 52 Week High
  • CCCX $14.90
  • OLMA $13.51
  • Technical
  • Relative Strength Index (RSI)
  • CCCX N/A
  • OLMA 77.80
  • Support Level
  • CCCX N/A
  • OLMA $8.01
  • Resistance Level
  • CCCX N/A
  • OLMA $11.50
  • Average True Range (ATR)
  • CCCX 0.00
  • OLMA 0.78
  • MACD
  • CCCX 0.00
  • OLMA 0.22
  • Stochastic Oscillator
  • CCCX 0.00
  • OLMA 88.57

About CCCX Churchill Capital Corp X Class A Ordinary Shares

Churchill Capital Corp X is a blank check company.

About OLMA Olema Pharmaceuticals Inc.

Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.

Share on Social Networks: